Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Acute Treatment with Rimegepant 75 mg Confers Long Term Improvements in Median Time to 30% and 50% Reductions in Monthly Migraine Days – Post Hoc Results from an Open Label Safety Study (BHVN-3000-201)
Headache
Headache Posters (7:00 AM-5:00 PM)
006

Rimegepant, a small molecule CGRP receptor blocker, is approved as an acute treatment and has demonstrated benefits in migraine prevention.  Preventive benefits of PRN dosing on time to 30% and 50% reduction in MMDs are unknown.

To describe long-term reductions in monthly migraine days (MMD) associated with acute treatment with rimegepant 75 mg.

The study population was derived from a multicenter, long-term (1 year), open-label safety study of rimegepant 75 mg oral tablet (NCT03266588). Eligible subjects included adults with ≥1 year history of migraine (ICHD-3 beta) who treated migraine attacks of any pain intensity with rimegepant 75 mg up to once daily as-needed (PRN) for up to 52 weeks. Kaplan-Meier analyses were used to assess median time to 30% and 50% MMD reduction in MMDs from baseline. Cluster analyses were used to identify 3 clusters based on baseline MMD.

Among 1,114 patients, the median (95%CI) time to a 30% reduction in MMDs was 8 (6-12) weeks and for a 50% reduction it was 20 (16-24) weeks. Among strata defined by baseline MMD, median time to 30% reduction was 8 (4-8) weeks for cluster 1 (8.1 MMD; n = 437), 12 (8-12) weeks for cluster 2 (10.4 MMD; n = 431), and 24 (24-36) weeks for cluster 3 (14.6 MMD; n = 246). Similar patterns of MMD change were observed for median time to 50% MMD reduction.

Repeated acute treatment of migraine with rimegepant 75 mg on a PRN basis, was associated with clinically relevant reductions in MMD without evidence of medication related increases in headache frequency.  These findings are consistent with preventive benefits of rimegepant 75 mg demonstrated in placebo controlled studies.

Authors/Disclosures
Gilbert J. L'Italien
PRESENTER
Gilbert J. L'Italien has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Gilbert J. L'Italien has stock in biohaven pharmaceuticals.
Evan Popoff Evan Popoff has nothing to disclose.
Nicole Kowalczyk Nicole Kowalczyk has nothing to disclose.
Diego Fernandez-Vial (University of Kentucky) Linda Harris has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Linda Harris has received stock or an ownership interest from Biohaven Pharmaceuticals.
Karissa Johnston Karissa Johnston has nothing to disclose.
Robert Croop, MD Dr. Croop has received personal compensation for serving as an employee of Biohaven Pharmaceuticals, Inc. Dr. Croop has received personal compensation for serving as an employee of Pfizer Inc.. Dr. Croop has stock in Biohaven Pharmaceutical Holding Co Ltd. Dr. Croop has stock in Biohaven Ltd.. Dr. Croop has received intellectual property interests from a discovery or technology relating to health care.
Vladimir Coric Vladimir Coric has received personal compensation for serving as an employee of Biohaven. Vladimir Coric has received personal compensation in the range of $1,000,000+ for serving as an officer or member of the Board of Directors for Bioahven. Vladimir Coric has stock in Biohaven. Vladimir Coric has received intellectual property interests from a discovery or technology relating to health care.